Alumis Inc

ALMS remains in Stage 2 – Advancing with an active Lockout Rally and bullish momentum. Price is pulling back into rising 9 and 20 EMAs while holding above the 50 DMA, offering a structural support entry. The Lockout Rally override sustains execution readiness despite overbought conditions, justifying a Buy Now posture. Key risks include potential deeper pullbacks through EMAs/50 DMA and moderate Stage Transition Risk to Stage 3 on repeated resistance tests.

• ↑Phase 3 trial for envudeucitinib in plaque psoriasis showed significant patient improvements, boosting approval odds.
• ↑Pipeline includes plaque psoriasis and SLE indications, offering diversified revenue potential.
• ↓Deeply negative profitability and earnings yield signal poor returns and capital inefficiency.